Compare HubSpot Inc (HUBS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Johnson & Johnson — how do they compare? HubSpot Inc trades at $210.8 (market cap $11.00B), while Johnson & Johnson trades at $260.79 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 56.9× HubSpot Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| HUBS | JNJ | |
|---|---|---|
Market Cap | $11.00B | $626.09B |
Sector | Technology | Health |
52-Week High | $522.97 | $267.24 |
52-Week Low | $170.39 | $174.16 |
Enterprise Value | $9.89B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $210.12, down 2.68% amid a bearish technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.26 versus $3.02 expected, but lowered its 2026 customer-growth forecast, causing investor concern. Revenue growth remains robust at 20% year-over-year, while profitability metrics show improvement, with net income margin rising to 4.26% in 2025 from negative figures in prior years.
The outlook is mixed: analyst consensus is bullish with a $233.93 price target, but near-term risks include execution challenges in AI adoption and a securities fraud investigation. Long-term growth depends on successful AI product integration and customer acquisition recovery, though competitive and regulatory pressures persist.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
